Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism

Current Diabetes Reviews

Volumn 10, Issue 5, 2014, Pages 327-335

  Abdulla, Haitham ^a   Phillips, Bethan ^a   Smith, Kenneth ^a   Wilkinson, Daniel ^a   Atherton, Philip J ^a   Idris, Iskandar ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Diabetes; Glucagon like peptide 1; Insulin; Microvascular blood flow; Microvascular recruitment; Skeletal muscle metabolism

Indexed keywords

AMINO ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE BLOOD LEVEL;

ARTERY DIAMETER; ARTICLE; BLOOD FLOW; FLOW RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SKELETAL MUSCLE; BLOOD FLOW VELOCITY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HOMEOSTASIS; HYPERGLYCEMIA; METABOLISM; MICROCIRCULATION; VASCULARIZATION;

BLOOD FLOW VELOCITY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN RESISTANCE; MICROCIRCULATION; MUSCLE, SKELETAL;

EID: 84925843375     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399810666141017153749     Document Type: Article

References (111)

1. Danaei G, Finucane MM, Lu Y, et al.National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. Danaei G, Singh GM, Paciorek CJ, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation 2013; 127: 1493-502, 1502e1-8.
3. Global health risks. Mortality and burden of disease attributable to selected major risks. Geneva: 2009.
4. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-58.
5. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 19-39.
6. Sinacore DR, Gulve EA. The role of skeletal muscle in glucose transport, glucose homeostasis, and insulin resistance: implications for physical therapy. Phys Ther 1993; 73: 878-91.
7. Nilsson M, Holst JJ, Björck IME. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks 1 - 3 2007: 996-1004.
8. Kopf A, Tchobroutsky G, Eschwege E. Serial postprandial blood glucose levels in 309 subjects with and without diabetes. Diabetes 1973; 22: 834-46.
9. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev 1987; 3: 415-59.
10. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
11. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88: 787-835, 9.
12. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 1982; 31: 957-63.
13. Moore MC, Cherrington AD, Wasserman DH. Regulation of hepatic and peripheral glucose disposal. Best Pract Res Clin Endocrinol Metab 2003; 17: 343-64.
14. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009; 32 Suppl 2: S157-63.
15. DeFronzo R a. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-87.
16. Baron AD, Brechtel G, Wallace P, Edelman S V. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 1988; 255: E769-74.
17. Fugmann A, Sarabi M, Karlström B, Berne C, Lithell H, Lind L. Blood flow is an important determinant of forearm glucose uptake following a mixed meal. Acta Diabetol 2003; 40: 113-7.
18. Høost U, Kelbaek H, Rasmusen H, et al.Haemodynamic effects of eating: the role of meal composition. Clin Sci 1996; 90: 269-76.
19. Clark MG. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. Am J Physiol Endocrinol Metab 2008; 295: E732-50.
20. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab 2011; 301: E252-63.
21. Delashaw JB, Duling BR. A study of the functional elements regulating capillary perfusion in striated muscle. Microvasc Res 1988; 36: 162-71.
22. Emerson GG, Segal SS. Alignment of microvascular units along skeletal muscle fibers of hamster retractor. J Appl Physiol 1997; 82: 42-8.
23. Honig CR, Odoroff CL, Frierson JL. Active and passive capillary control in red muscle at rest and in exercise. Am J Physiol 1982; 243: H196-206.
24. Sarelius IH. Cell and oxygen flow in arterioles controlling capillary perfusion. Am J Physiol 1993; 265: H1682-7.
25. Vincent MA, Clerk LH, Lindner JR, et al.Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004; 53: 1418-23.
26. Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S, Barrett EJ. The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake. Diabetes Metab Res Rev n.d.; 20: 3-12.
27. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006; 55: 1436-42.
28. Rennie MJ. Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover. Appl Physiol Nutr Metab 2009; 34: 377-81.
29. Guillet C, Zangarelli A, Gachon P, et al.Whole body protein breakdown is less inhibited by insulin, but still responsive to amino acid, in nondiabetic elderly subjects. J Clin Endocrinol Metab 2004; 89: 6017-24.
30. Rasmussen BB, Fujita S, Wolfe RR, et al.Insulin resistance of muscle protein metabolism in aging. FASEB J 2006; 20: 768-9.
31. Wilkes EA, Selby AL, Atherton PJ, et al.Blunting of insulin inhibition of proteolysis in legs of older subjects may contribute to age-related sarcopenia. Am J Clin Nutr 2009; 90: 1343-50.
32. Jackson RA, Hawa MI, Roshania RD, Sim BM, DiSilvio L, Jaspan JB. Influence of aging on hepatic and peripheral glucose metabolism in humans. Diabetes 1988; 37: 119-29.
33. Lanza IR, Short DK, Short KR, et al.Endurance exercise as a countermeasure for aging. Diabetes 2008; 57: 2933-42.
34. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003; 284: E7-12.
35. Davidson MB. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism 1979; 28: 688-705.
36. Houmard JA, Weidner MD, Dolan PL, et al.Skeletal muscle GLUT4 protein concentration and aging in humans. Diabetes 1995; 44: 555-60.
37. Proctor DN, Shen PH, Dietz NM, et al.Reduced leg blood flow during dynamic exercise in older endurance-trained men. J Appl Physiol 1998; 85: 68-75.
38. Donato AJ, Uberoi A, Wray DW, Nishiyama S, Lawrenson L, Richardson RS. Differential effects of aging on limb blood flow in humans. Am J Physiol Heart Circ Physiol 2006; 290: H272-8.
39. Skilton MR, Lai NT, Griffiths KA, et al.Meal-related increases in vascular reactivity are impaired in older and diabetic adults: insights into roles of aging and insulin in vascular flow. Am J Physiol Heart Circ Physiol 2005; 288: H1404-10.
40. Timmerman KL, Lee JL, Dreyer HC, et al.Insulin stimulates human skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of rapamycin complex 1 signaling. J Clin Endocrinol Metab 2010; 95: 3848-57.
41. Guillet C, Delcourt I, Rance M, Giraudet C, Walrand S, Bedu M, et al.Changes in basal and insulin and amino acid response of whole body and skeletal muscle proteins in obese men. J Clin Endocrinol Metab 2009; 94: 3044-50.
42. Deutz NEP, Safar A, Schutzler S, et al.Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 2011; 30: 759-68.
43. Toth MJ, LeWinter MM, Ades P a, Matthews DE. Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation. Clin Sci (Lond) 2010; 119: 467-76.
44. Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, et al.Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J 2005; 19: 422-4.
45. Glover EI, Phillips SM, Oates BR, et al.Immobilization induces anabolic resistance in human myofibrillar protein synthesis with low and high dose amino acid infusion. J Physiol 2008; 586: 6049-61.
46. Bennet WM, Connacher a a, Jung RT, Stehle P, Rennie MJ. Effects of insulin and amino acids on leg protein turnover in IDDM patients. Diabetes 1991; 40: 499-508.
47. La Barre J. Sur les possibilite´s d’un traitement du diabète par l'incrétine. Bull Acad R Med Belg 1932; 12: 620-32.
48. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. lancet 1964; 2: 20-1.
49. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma Insulin Response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-82.
50. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-8.
51. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-4.
52. Gautier J-F, Choukem S-P, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34 Suppl 2: S65-72.
53. Nauck MA, Homberger E, Siegel EG, et al.Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8.
54. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide- 1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-32.
55. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39.
56. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-24.
57. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994; 37: 1163-6.
58. Bullock P, Scott R, Habener JF. Tissue Distribution of Messenger Ribonucleic Acid Receptor Encoding the rat Glucagon-Like Peptide-1 Receptor. Endocrinology 1996; 137: 2968-78.
59. Nyström T, Gutniak MK, Zhang Q, et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-15.
60. Luque MA, Gonzalez N, Marquez L, et al.Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 2002; 173: 465-73.
61. Mandarino LJ, Madar Z, Kolterman OG, Bell JM, Olefsky JM. Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic subjects. Am J Physiol 1986; 251: E489-96.
62. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010; 2010: 476279.
63. Acitores A, Gonzalez N, Sancho V, Valverde I, Villanueva- Penacarrillo ML. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J Endocrinol 2004; 180: 389-98.
64. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al.Exendin-4 is a high potency agonist and truncated exendin-(9-39)- amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-5.
65. Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab 2009; 94: 3543-9.
66. Chai W, Dong Z, Wang N, et al.Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012; 61: 888-96.
67. Moreno P, Nuche-Berenguer B, Gutiérrez-Rojas I, et al.Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states. J Mol Endocrinol 2012; 48: 37-47.
68. Giannocco G, Oliveira KC, Crajoinas RO, et al.Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol 2013; 698: 74-86.
69. Sjøberg K a, Holst JJ, Rattigan S, Richter E a, Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab 2014; 306: E355-62.
70. Subaran SC, Sauder MA, Chai W, et al.GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond) 2014; 127: 163-70.
71. Chai W, Wang W, Dong Z, Cao W, Liu Z. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. Diabetes 2011; 60: 2939-46.
72. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-95.
73. Yang D, Nakajo Y, Iihara K, Kataoka H, Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res 2013; 1517: 104-13.
74. Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P, et al.Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 2014; 13: 19.
75. Villanueva-Peñacarrillo ML, Martín-Duce A, Ramos-Álvarez I, Gutiérrez-Rojas I, Moreno P, Nuche-Berenguer B, et al.Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regul Pept 2011; 168: 39-44.
76. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009; 150: 1155-64.
77. Johnson KMS, Edgerton DS, Rodewald T, et al.Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 2007; 293: E1085-91.
78. Tesauro M, Schinzari F, Adamo A, et al.Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 2013; 36: 683-9.
79. Green CJ, Henriksen TI, Pedersen BK, Solomon TP. Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS One 2012; 7: e44284.
80. Bertin E, Arner P, Bolinder J, Hagstrom-Toft E. Action of Glucagon and glucagon-Like Peptide-1-(7-36) Amide on Lipolysis in Human Subcutaneous Adipose Tissue and Skeletal Muscle in Vivo *. J Clin Endocrinol Metab 2001; 86: 1229-34.
81. Bohé J, Low JF, Wolfe RR, Rennie MJ. Latency and duration of stimulation of human muscle protein synthesis during continuous infusion of amino acids. J Physiol 2001; 532: 575-9.
82. Børsheim E, Cree MG, Tipton KD, Elliott T a, Aarsland A, Wolfe RR. Effect of carbohydrate intake on net muscle protein synthesis during recovery from resistance exercise. J Appl Physiol 2004; 96: 674-8.
83. Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH. Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. Am J Clin Nutr 2010; 91: 966-75.
84. Morifuji M, Ishizaka M, Baba S, Fukuda K, Matsumoto H, Koga J, et al.Comparison of different sources and degrees of hydrolysis of dietary protein: effect on plasma amino acids, dipeptides, and insulin responses in human subjects. J Agric Food Chem 2010; 58: 8788-97.
85. Gweon H-S, Sung H-J, Lee D-H. Short-term protein intake increases fractional synthesis rate of muscle protein in the elderly: meta-analysis. Nutr Res Pract 2010; 4: 375-82.
86. Tang JE, Moore DR, Kujbida GW, Tarnopolsky MA, Phillips SM. Ingestion of whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein synthesis at rest and following resistance exercise in young men. J Appl Physiol 2009; 107: 987-92.
87. Kornasio R, Riederer I, Butler-Browne G, Mouly V, Uni Z, Halevy O. Beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways. Biochim Biophys Acta 2009; 1793: 755-63.
88. Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasomeinduced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}- methylbutyrate in cancer-induced muscle loss. Cancer Res 2005; 65: 277-83.
89. Staples AW, Burd N a, West DWD, et al.Carbohydrate does not augment exercise-induced protein accretion versus protein alone. Med Sci Sports Exerc 2011; 43: 1154-61.
90. Figueiredo VC, Cameron-Smith D. Is carbohydrate needed to further stimulate muscle protein synthesis/hypertrophy following resistance exercise? J Int Soc Sports Nutr 2013; 10: 42.
91. Drummond MJ, Rasmussen BB. Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis. Curr Opin Clin Nutr Metab Care 2008; 11: 222-6.
92. Cahill GF. Physiology of insulin in man. Diabetes 1971; 20: 785-99.
93. Pain VM, Garlick PJ. Effect of streptozotocin diabetes and insulin treatment on the rate of protein synthesis in tissues of the rat in vivo. J Biol Chem 1974; 249: 4510-4.
94. Pain VM, Albertse EC, Garlick PJ. Protein metabolism in skeletal muscle, diaphragm, and heart of diabetic rats. Am J Physiol 1983; 245: E604-10.
95. Garlick PJ, Grant I. Amino acid infusion increases the sensitivity of muscle protein synthesis in vivo to insulin. Effect of branchedchain amino acids. Biochem J 1988; 254: 579-84.
96. Biolo G, Williams BD, Fleming RY, Wolfe RR. Insulin action on muscle protein kinetics and amino acid transport during recovery after resistance exercise. Diabetes 1999; 48: 949-57.
97. Pacy PJ, Nair KS, Ford C, Halliday D. Failure of Insulin Infusion to Stimulate Fractional Muscle Protein Synthesis in Type I Diabetic Patients; Anabolic Effect of Insulin and Decreased Proteolysis 1989; 38: 612-24.
98. Tessari P, Biolo G, Inchiostro S, Saccà L, Nosadini R, Boscarato MT, et al.Effects of insulin on whole body and forearm leucine and KIC metabolism in type 1 diabetes. Am J Physiol 1990; 259: E96-103.
99. Louard RJ, Fryburg DA, Gelfand RA, Barrett EJ. Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle. J Clin Invest 1992; 90: 2348-54.
100. Bell JA, Volpi E, Fujita S, et al. Skeletal Muscle Protein Anabolic Response to Increased Energy and Insulin Is Preserved in Poorly Controlled Type 2 Diabetes 2006: 1249-55.
101. Barazzoni R, Short KR, Asmann Y, Coenen-Schimke JM, Robinson MM, Nair KS. Insulin fails to enhance mTOR phosphorylation, mitochondrial protein synthesis, and ATP production in human skeletal muscle without amino acid replacement. Am J Physiol Endocrinol Metab 2012; 303: E1117-25.
102. Fujita S, Rasmussen BB, Cadenas JG, Grady JJ, Volpi E. Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability. Am J Physiol Endocrinol Metab 2006; 291: E745-54.
103. Sakurai Y, Aarsland A, Herndon DN, et al.Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients. Ann Surg 1995; 222: 283-94; 294-7.
104. Hillier TA, Fryburg DA, Jahn LA, Barrett EJ, Teresa A. Extreme hyperinsulinemia unmasks insulin ’ s effect to stimulate protein synthesis in the human forearm. Am J Physiol Endocrinol Metab 1998; 247: E1067-74.
105. Ferrando A, Chinkes DL, Wolf SE, Matin S, Herndon DN, Wolfe RR. A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. Ann Surg 1999; 229: 11-8.
106. Guillet C, Prod’homme M, Balage M, et al.Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans. FASEB J 2004; 18: 1586-7.
107. Bell JA, Fujita S, Volpi E, Cadenas JG, Rasmussen BB. Short-term insulin and nutritional energy provision do not stimulate muscle protein synthesis if blood amino acid availability decreases. Am J Physiol Endocrinol Metab 2005; 289: E999-1006.
108. Greenhaff PL, Karagounis LG, Peirce N, et al.Disassociation between the effects of amino acids and insulin on signaling , ubiquitin ligases , and protein turnover in human muscle. Am J Physiol Endocrinol Metab 2008; 295: 595-604.
109. Smith GI, Atherton P, Reeds DN, et al.No major sex differences in muscle protein synthesis rates in the postabsorptive state and during hyperinsulinemia-hyperaminoacidemia in middle-aged adults. J Appl Physiol 2009; 107: 1308-15.
110. Gelfand R a, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest 1987; 80: 1-6.
111. Chow LS, Albright RC, Bigelow ML, et al.Mechanism of insulin s anabolic effect on muscle: measurements of muscle protein synthesis and breakdown using aminoacyl-tRNA and other surrogate measures. Am J Physiol - Endocrinol Metab 2006; 291: 729-36.